Pulmonology

Your Article Summary

See Latest Articles

HOXB2 as a Novel Prognostic Indicator for Stage I Lung Adenocarcinomas
Journal of Thoracic Oncology, 09/11/07

Inamura, K., et al. - Conclusions: We document evidence that p-stage I patients with HOXB2 up-regulation have a worse prognosis than those with HOXB2 down-regulation (p = 0.0065), whereas the HOXB2 status has no prognostic significance for p-stage II-IV patients. Comparing tumors and corresponding normal lung tissue, we confirmed HOXB2 up-regulated lesions to have much higher HOXB2 expression than the corresponding normal tissue. Confirmation with a larger number of samples is needed, with further research to clarify the molecular functions of HOXB2

Today in Basic Science/Genetics...keeping you current

Receive free subspecialty "5-minute updates" via email

Polymorphisms in the CASPASE Genes and Survival in Patients With Early-Stage Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 10/16/09

Absence of inflammation and pneumonia during infection with non-pigmented Yersinia pestis reveals new role for the pgm locus in pathogenesis
Infection and Immunity, 10/30/09

Association and interaction analyses of eight genes under asthma linkage peaks
Allergy, 10/15/09

See All of Basic Science/Genetics

Today in Lung/Thoracic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09

See All of Lung/Thoracic Oncology